DMSO · Atlas

1. Introduction

Version followed: DMSO as regulators and clinical references describe it (US Rimso-50 prescribing information; Memorial Sloan Kettering "About Herbs", updated July 2023; Health Canada status as summarised by the Canadian Armed Forces Force Health Protection Directorate; TGA), set against the self-administered "cure-all" use promoted by sellers and on social media. This guide sets out the psychotherapist's own work alongside it: the psychotherapist works with the client who uses or is considering DMSO, and never supplies, applies, recommends or advises on it.

Dimethyl sulfoxide (DMSO) is an industrial solvent, originally a by-product of paper manufacturing, that is absorbed rapidly through the skin and can carry other dissolved substances with it [source: MSK; Canadian Force Health Protection DMSO information sheet]. In medicine it has narrow, prescribed uses: a bladder instillation for interstitial cystitis (the only FDA-approved therapeutic indication), hospital management of chemotherapy extravasation, a cryoprotectant for stored stem cells, and a solvent in an approved topical pain product [source: Rimso-50 label; MSK; Science Feedback 2025]. Outside medicine it has been promoted since the 1960s as a near-universal remedy for pain, arthritis, injuries and cancer, often with a story that regulators suppressed it [source: McGill OSS, Jarry 2023; Demagog 2023].

Core idea as promoters hold it: DMSO reduces pain and inflammation, "traps" free radicals, and drives other substances through the skin, so applied alone or combined with other products it is claimed to relieve many conditions. These are attributed claims; MSK states "There is no evidence that DMSO can treat cancer in humans" [source: MSK]. Nothing in this guide presents DMSO as a treatment for cancer or any other physical disease.

The psychotherapist's own model of change here [synthesis]: change comes from a non-judgemental conversation in which the client's reasons for using DMSO are understood, accurate attributed information is available, the client's doctor or pharmacist is involved with consent, and risks (abandoned medical care, contaminated products, exploitation) are recognised early.

2. Framework

The method as its sources describe it

Theory (attributed): a solvent with membrane-penetrating, claimed anti-inflammatory, analgesic and antioxidant properties; the garlic-like taste and body odour come from a metabolite (dimethyl sulfide) breathed out and lost through the skin [source: MSK; Rimso-50 label].
What a client experiences, consumer use: liquids, gels, creams, salves and roll-ons bought online and applied to the skin; some promoters also urge taking it by mouth or combining it with other products (ivermectin, fenbendazole, vitamin C, sodium chlorite "MMS") [source: Science Feedback 2025; US v. Lehan Enterprises complaint 2015; Demagog 2023; TGA 2020]. Common experiences reported: garlic taste and breath, skin burning, redness, itching or dryness, nausea [source: Rimso-50 label; Kollerup Madsen et al. 2019; MSK].
What a patient experiences, prescribed use: a urologist instils the prescription product into the bladder by catheter; patients often notice garlic-like taste and odour on breath and skin, and transient bladder discomfort; the label advises eye examinations and periodic blood, liver and kidney testing [source: Rimso-50 label].
Who practises or promotes it: prescribed use by urologists and hospital teams; non-medical use promoted by online sellers, social-media accounts and some "natural medicine" clinics [source: Science Feedback 2025; Demagog 2023]. There is no professional body or recognised training route for non-medical DMSO use [uncertain: not verified].

Regulation (one line each)

United States: prescription Rimso-50 is approved only for symptomatic relief of interstitial cystitis and "has not been approved as being safe and effective for any other indication"; MSK states DMSO is not approved for over-the-counter use in any form [source: Rimso-50 label; MSK]. FDA and FTC have acted against sellers making disease claims (joint warning letter 2011; DOJ complaint 2015) [source: US v. Lehan Enterprises complaint].
Canada: approved only for certain genitourinary conditions and for preserving cells for transplant; prescription only [source: Canadian Force Health Protection information sheet].
Australia: DMSO is not on the Australian Register of Therapeutic Goods and cannot lawfully be sold as a therapeutic good; in 2020 the Federal Court restrained a seller from advertising and supplying DMSO and MMS [source: TGA media release 2020].
United Kingdom: not in the British National Formulary and not routinely used, per the Faculty of Pain Medicine as reported by Science Feedback [source: Science Feedback 2025] [uncertain: secondary].
Poland: not on the register of authorised medicinal products [source: Demagog 2023]; forensic toxicologists state that neither DMSO nor perhydrol (hydrogen peroxide) products are authorised for marketing in Poland [source: Rzepczyk et al. 2023]. In 2026 prosecutors in Nowy Sącz charged a non-medical practitioner with fraud, exposing patients to danger to life or serious harm, and providing health services without authorisation, over intravenous drips containing DMSO given to people with serious illness including cancer; she was barred from paramedical activity pending the case [source: TVN24 2026].
Veterinary: used for pain and inflammation in animals [source: Science Feedback 2025].

Evidence status (one line each)

Interstitial cystitis: approved use; MSK calls supporting evidence "not definitive" [source: MSK].
Pain and osteoarthritis: scarce and inconclusive; a 2009 trial found DMSO alone no better than placebo [source: Science Feedback 2025; McGill OSS 2023].
Cancer: no evidence of benefit in humans [source: MSK].
Safety: most reported reactions in clinical studies are mild and transient, with cardiovascular and respiratory reactions mainly after intravenous use; studies carry a high risk of bias [source: Kollerup Madsen et al. 2019].

The psychotherapist's framework alongside it [synthesis]

No source sets phases for this work; the structure below is synthesis built from general psychotherapy practice.

Inquiry and recording (first session or whenever a health product comes up). Goal: know what is used, why, from where. Move on once use, source and purpose are recorded.
Understanding meaning (folded into ongoing therapy). Goal: the client's explanatory model, hopes and what DMSO represents (control, hope, distrust, belonging). Move on when the client feels understood rather than judged.
Informed, values-based decision (as needed). Goal: the client weighs their own priorities with accurate attributed information; the decision stays theirs.
Coordination (with consent, any time). Goal: the prescriber or pharmacist knows about the use.
Risk monitoring and follow-up (ongoing). Goal: early recognition of delayed medical care, adverse effects, exploitation, safeguarding concerns. Urgent physical symptoms override every phase.

3. Guiding principles

Curiosity before information. Ask what DMSO means to the client before offering anything; lectures close the conversation [synthesis].
Attribute, do not adjudicate. Present claims as "promoters say" and regulatory facts as "the FDA/TGA states"; neither endorse nor ridicule [synthesis].
Stay in scope. Never recommend, supply, apply, prescribe or advise on starting, stopping or changing DMSO or any medicine; route those questions to the prescriber or pharmacist [synthesis, consistent with the label's advice to tell the physician about all medicines: source: Rimso-50 label].
Autonomy without abandonment. The client decides; the therapist keeps the door open and keeps safety in view [synthesis].
Safety overrides neutrality. Abandoned cancer care, a child or pregnancy, acute reactions or contaminated product move the conversation from exploration to active risk response [synthesis; pregnancy and contamination warnings: source: MSK].
Collaborate with medicine. With consent, the doctor or pharmacist is a partner, not an adversary [synthesis].
No commercial interest. The therapist never sells or refers to sellers of products, courses or clinics, and declares any conflict [synthesis].
Name the distrust respectfully. Suppression narratives are a recurring feature of DMSO promotion; treat the client's distrust as meaningful and explore it [source for the narrative: McGill OSS 2023; Demagog 2023; stance: synthesis].
Document plainly. Record the product, source, purpose, information given and coordination agreed, in neutral language [synthesis].

4. Intervention inventory

All interventions below are the psychotherapist's own work alongside DMSO use. Facts about DMSO are cited; the clinical procedures are [synthesis] unless a source is named. The therapist never performs, sells, prescribes or recommends DMSO.

4.1 Routine, non-judgemental inquiry and recording

Purpose / when: at intake and whenever pain, injury, cancer, bladder symptoms, sport or online health content comes up. DMSO is often bought online and used without a doctor knowing [source for online supply: US v. Lehan Enterprises complaint; Canadian Force Health Protection sheet; inquiry: synthesis].
Steps: (1) Normalise: say many clients use products alongside medical care. (2) Ask openly about anything taken, rubbed on or used for health, including solvents such as DMSO and products bought online. (3) Record name, form (liquid, gel, cream, roll-on), where obtained (pharmacy prescription, online seller, clinic, friend), what it is for, whether combined with anything, and whether the doctor knows. (4) Do not ask for or record amounts or methods beyond what is needed for coordination. (5) Thank the client for telling you.
Example language (illustrative): "Lots of people use things for pain or health that their doctor hasn't prescribed. Is there anything like that for you, creams, liquids, things from online, DMSO, anything at all?" / "Where did you get it from? I ask because where it comes from can matter for your doctor."
Watch for: defensiveness (slow down and reassure); mention of "industrial", "pure solvent" or unlabelled bottles (contamination risk: industrial grade is not meant for humans and DMSO can carry dissolved contaminants through the skin [source: Canadian Force Health Protection sheet; MSK]); combination with other products; use for cancer. Working: the client volunteers updates in later sessions.

4.2 Exploring meaning, hopes and the explanatory model

Purpose / when: once use is known, before any information is offered.
Steps: (1) Ask what led them to DMSO and who introduced it (influencer, friend, practitioner, sports team). (2) Ask what they hope it will do and how they will know. (3) Ask what it means: control over pain, hope in illness, distrust of doctors or regulators, identity, belonging to an online community. (4) Reflect the need under the choice (relief, agency, being taken seriously). (5) Ask what their doctors have said and how that felt.
Example language (illustrative): "What drew you to DMSO, what did you hear about it that made sense?" / "It sounds like what matters most is having something you can do yourself when the pain flares." / "Some of what you've read says doctors don't want people to know about it. What's your own experience been with doctors?"
Watch for: suppression narratives (FDA 'banned' it, 'big pharma' hides it), which are recurrent in DMSO promotion [source: Demagog 2023; McGill OSS 2023]; hopelessness behind a cancer-related use; unmet pain needs. Working: the client speaks openly about doubts as well as hopes.

4.3 Sharing attributed information (only with permission)

Purpose / when: when the client asks, or when a safety-relevant gap is evident and the client agrees to hear it.
Steps: (1) Ask permission. (2) Ask what they already know. (3) Offer one or two attributed facts in plain language, e.g. the only approved use is a prescribed bladder treatment; the US label lists eye-test and blood-test monitoring for prescribed use; MSK states there is no evidence it treats cancer in humans; industrial grade may be contaminated [source: Rimso-50 label; MSK]. (4) Ask what they make of it. (5) Offer the written sources rather than your opinion.
Example language (illustrative): "Would it be useful if I shared what the regulators and a cancer centre say about it? You can make of it what you like." / "What do you make of that?"
Watch for: information delivered as persuasion (rupture risk); a sense of being 'caught'. Never advise on whether to continue; route that to the prescriber or pharmacist. Working: the client compares sources themselves.

4.4 Supporting an informed, values-based decision without coercion

Purpose / when: when the client is weighing DMSO against, or alongside, medical care, especially for cancer, chronic pain or interstitial cystitis.
Steps: (1) Clarify the decision in the client's words. (2) Elicit their values (living longer, comfort, independence, avoiding side effects, family). (3) Map options as the client sees them, including asking their doctor about prescribed options. (4) Identify what information they still need and who can give it (oncologist, urologist, pharmacist). (5) Check for pressure from sellers, groups or family. (6) Leave the decision with the client and agree a follow-up. No published decision aid specific to DMSO is cited here [uncertain: not verified].
Example language (illustrative): "If you imagine looking back on this in a year, what would you want to have weighed most?" / "Who could answer the medical part of this question for you?"
Watch for: decisions to stop or delay effective treatment (escalate to 4.6); pressure to decide fast; financial strain. Working: the decision is articulated in the client's own values and their doctor is involved.

4.5 Coordinating with the doctor or pharmacist (with consent)

Purpose / when: whenever DMSO is used alongside prescribed medicines, during cancer treatment, in pregnancy, or when side effects are reported.
Steps: (1) Explain why: the US label notes DMSO may potentiate other medicines and asks patients to tell their physician about all medicines; a laboratory study found DMSO inactivated certain platinum chemotherapy drugs; some products reportedly contain undeclared ingredients [source: Rimso-50 label; Science Feedback 2025 citing Hall et al. 2014; Canadian Force Health Protection sheet]. (2) Obtain written consent specifying what is shared. (3) Encourage the client to tell the prescriber directly, and offer to write or call as well. (4) Share facts only (product, source, purpose), not your judgement of it. (5) Record the outcome.
Example language (illustrative): "Because it soaks through the skin and can affect how other medicines work, your doctor or pharmacist really needs to know. Would you be willing to tell them, or would you like me to with your permission?"
Watch for: refusal of consent (respect it, keep discussing, document; act without consent only under safeguarding or imminent-risk law); being drawn into giving medical advice. Working: the prescriber acknowledges and the client reports a joint plan.

4.6 Recognising and responding to risk

Purpose / when: throughout; immediately when any red flag below appears.
Red flags and why [facts sourced as marked; responses: synthesis]:
- Stopping or delaying medical care, especially cancer treatment; sellers have advised a person with cancer against chemotherapy, radiation and surgery [source: US v. Lehan Enterprises complaint].
- Use for cancer, or combined with ivermectin, fenbendazole, vitamin C or sodium chlorite (MMS) [source: Science Feedback 2025; TGA 2020]; see the chlorine dioxide and alternative-cancer entries in this domain.
- Pregnancy or breastfeeding: MSK advises pregnant women to avoid it; animal studies showed birth defects; safety in breastfeeding is unknown [source: MSK; Rimso-50 label].
- Children: safety and effectiveness have not been established [source: Rimso-50 label].
- Industrial-grade, black-market or unlabelled product [source: Canadian Force Health Protection sheet].
- Symptoms the client links to use: rash or blistering, breathing difficulty, facial swelling, severe dizziness, visual changes, dark urine, severe headache or confusion. The sources report hypersensitivity and histamine release, colour-vision changes and transient red-cell breakdown, and a case report of recurrent brain haemorrhage [source: Rimso-50 label; Canadian Force Health Protection sheet; MSK].
- Injury masking in athletes or military personnel continuing to train [source: Canadian Force Health Protection sheet].
- Intravenous administration at a non-medical clinic [synthesis; see Harm account].
- Heavy spending, recruitment to sell, or group pressure.
Steps: (1) Name the concern calmly and specifically. (2) For acute symptoms: urge immediate emergency or poison-centre contact and stay with the client until help is arranged. (3) For abandoned or delayed treatment: ask permission to involve the treating team; explore fears driving the choice (side effects, loss of control, prior bad experiences). (4) For children: follow safeguarding (4.9). (5) Document what was said and agreed.
Example language (illustrative): "What you're describing, the swelling and trouble breathing, needs a doctor right now. Can we call together?" / "I'm not going to tell you what to take, but I am worried about the cancer treatment being put on hold. Can we talk about what's making that feel like the right move?"
Watch for: minimisation, secrecy, the client avoiding sessions after you raised concern. Working: risks are named openly and the treating team is involved.

4.7 Financial exploitation, commerce and group dynamics

Purpose / when: when the client buys repeatedly from online sellers, follows a 'protocol' influencer, belongs to a protocol group, or is recruited to resell.
Steps: (1) Ask about spending and how purchases are funded. (2) Explore the online or in-person community: what it gives (hope, belonging) and what it asks (loyalty, distrust of outsiders, secrecy from doctors). (3) Note testimonial-driven persuasion, which has replaced evidence in DMSO advocacy since the 1960s [source: McGill OSS 2023]. (4) Support the client to keep other relationships and sources of information. (5) Never sell or endorse any product, course or practitioner; declare any conflict of interest [synthesis; on multiple relationships see the APA Ethics Code, Standard 3.05].
Example language (illustrative): "How much has this cost you so far, and how is that sitting with you?" / "What happens in the group if someone has doubts?"
Watch for: debt, isolation, pressure to recruit, shame. Working: the client can voice doubts and set limits.

4.8 Health anxiety, chronic pain and somatic presentations

Purpose / when: when DMSO use is driven by persistent pain, bladder pain syndrome, unexplained symptoms or health anxiety. Use the established psychological approaches in Domain II (CBT for health anxiety, somatic symptom and chronic-pain approaches) [cross-reference: Domain II].
Steps: (1) Validate the symptoms as real. (2) Map the cycle of symptom, worry, checking or self-treatment and short-term relief. (3) Agree goals in terms of functioning and quality of life. (4) Apply the Domain II protocol, coordinating with the treating clinician. (5) Treat repeated product-seeking as information about distress, not as a target for persuasion.
Example language (illustrative): "The pain is real, and it makes sense you'd look for anything that helps. Can we also look at what the pain is costing you day to day?"
Watch for: escalation to multiple products; reassurance seeking. Working: less preoccupation, better functioning.

4.9 Children, consent and safeguarding

Purpose / when: a parent applies or gives DMSO to a child, or withholds medical care in favour of it.
Steps: (1) Ask neutrally what the child is given and why. (2) Note that safety in children has not been established [source: Rimso-50 label]. (3) Encourage the parent to involve the child's doctor. (4) Hear the child's own view at an age-appropriate level (assent). (5) If a child is given a harmful or contaminated product or deprived of needed medical care, follow local safeguarding procedures and consult your safeguarding lead. Never name the child in external notes beyond what the referral requires [synthesis].
Example language (illustrative): "Does your child's doctor know about it? Because children's bodies handle substances differently, I'd want them in the loop."
Watch for: refusal of medical review; signs of neglect. Working: the child's doctor is involved.

4.10 Psycho-oncology conversations

Purpose / when: a client with cancer uses or considers DMSO, alone or in a social-media 'protocol'.
Steps: (1) Hold a respectful conversation about why alternatives appeal. (2) Encourage the client to tell the oncology team and to ask them about integrative oncology services that work alongside, never instead of, standard care (see entry 172). (3) Offer palliative-care referral information where relevant. (4) Work with family conflict about the choice. (5) Be ready for grief, guilt and regret if an alternative was chosen and disease progressed.
Example language (illustrative): "You want to fight this in a way that feels like yours. Would your oncologist be someone you could talk this through with?"
Watch for: delayed treatment, family splits, hopelessness. Working: the oncology team is informed and the client feels accompanied rather than judged.

4.11 Reporting routes

Purpose / when: a product causes harm, is sold with disease claims, or a practitioner administers it unlawfully.
Steps: (1) Discuss with the client and, where possible, obtain consent. (2) Products and adverse effects: the national medicines regulator (US FDA; Health Canada; TGA in Australia; MHRA in the UK) [regulators' roles: source: Rimso-50 label; TGA 2020]. In the US, consumers, patients and health professionals can make voluntary MedWatch reports online, on the consumer Form FDA 3500B or by phone; MedWatch covers serious reactions, product quality problems and use errors for drugs, devices, dietary supplements and cosmetics [source: FDA, Reporting Serious Problems to FDA]. In the UK, patients, the public and professionals can report suspected side effects (including to herbal and homeopathic remedies), defective medicines and falsified products through the MHRA Yellow Card website or app [source: MHRA Yellow Card guidance]. Other countries' forms [uncertain]. (3) Misleading advertising: consumer and advertising regulators (in the US the FTC has acted jointly with the FDA on DMSO claims) [source: US v. Lehan Enterprises complaint]. (4) Regulated health professionals: their licensing board. (5) Children: safeguarding services. (6) Document what was reported and to whom.
Example language (illustrative): "Would you be willing for us to report this product to the regulator? It could protect other people."
Watch for: fear of retaliation from a seller or group. Working: report filed and the client feels supported.

4.12 Documentation and boundaries

Purpose / when: every contact where DMSO is discussed.
Steps: record product, source, purpose, risks noted, information given (with source), consent and coordination; keep notes factual; never record your own recommendation for or against use because none is given.
Example language (illustrative): "I'll note that we talked about DMSO and that you'll mention it to your GP. Is that a fair summary?"
Watch for: drift into advisor role. Working: notes would let a colleague pick up safely.

5. Handling problems

The sources do not address psychotherapy problems directly; all responses here are [synthesis] unless marked.

Client hides use, then discloses late. Thank them; avoid 'why didn't you tell me'. Ask what made it hard to say; explore fear of judgement. Resume 4.1 and 4.5.
Client asks you whether to use it, or for 'how much'. Decline warmly and clearly: it is outside your role; route to the prescriber or pharmacist. Do not give amounts, sources or methods. "That's a question I'm not the right person for, and I don't want to guess with your health. Your pharmacist can answer it properly (illustrative)."
Client asks you to tell their doctor it is fine. Refuse to endorse; offer to share facts with consent.
Resistance to any information ('the FDA lies'). Do not argue. Return to meaning (4.2): what experiences built that distrust? Keep the relationship as the protective factor. DMSO's regulatory history (the 1965 FDA action and later restrictions) is a common basis for these narratives, so acknowledge that history is real while noting how it is used [source for history: McGill OSS 2023].
Rupture after you raise risk. Name it: "I think I came on strong last time. I'd like to understand what that was like for you (illustrative)." Re-affirm the client's autonomy and your concern.
Stuck: client cycles between hope and despair (often in cancer or chronic pain). Slow down; focus on values and what gives life meaning now; consider palliative or pain-service links through the treating team (4.10, 4.8).
Overwhelm from conflicting online information. Reduce inputs: agree one or two trusted sources, one question for the doctor, and a pause on new decisions until the next session.
Non-adherence to medical care alongside DMSO. Explore barriers (side effects, cost, access, prior harm); coordinate with consent; do not frame DMSO as the 'cause' unless the client does.
Acute adverse symptoms mid-session. Stop the session's agenda; arrange emergency or poison-centre contact (4.6). Flag: hypersensitivity reactions are documented [source: Rimso-50 label].
Product is industrial or black-market. Name the specific contamination risk (contaminants carried through the skin) as the source states it, and encourage the client to talk to a pharmacist [source: Canadian Force Health Protection sheet].
Combined with other harmful products (sodium chlorite/chlorine dioxide, antiparasitics for cancer). Treat as a high-risk situation; see the corresponding entries in this domain; involve the treating team with consent [source for combinations: TGA 2020; Science Feedback 2025].
Family conflict over a relative's use. Meet the family's fear and the user's autonomy; help them separate care from control; avoid triangulation.
Client wants you to join or endorse a group or buy a product. Decline; name the boundary; explore what endorsement would mean to them.
Pregnancy disclosed. Encourage immediate discussion with the maternity clinician; MSK advises avoidance in pregnancy [source: MSK].
Therapist's own reactions (frustration, alarm, ridicule). Use supervision; check for contempt leaking into language.

Harm account

What was actually done

Early 1960s, Oregon, USA. DMSO, a waste by-product at the Crown Zellerbach paper company, was investigated by staff chemist Robert Herschler and surgeon Stanley Jacob, who was studying cryopreservation for transplantation [source: McGill OSS 2023]. In 1963 front-page coverage in The New York Times and in Newsweek and Life presented it as a wonder drug; Crown issued research licences to six pharmaceutical companies, Schering marketed it in Germany in 1965, and Merck, Squibb and Syntex filed US applications [source: McGill OSS 2023].
1965. After a University of Pennsylvania veterinarian reported abnormal eye changes in laboratory animals, the FDA denied Merck's application and cancelled Crown's power to issue research contracts. A woman in Ireland was reported to have died three days after applying DMSO to a sprained wrist, possibly from allergy. In November 1965 the FDA telegraphed US doctors, embassies and the WHO warning of eye toxicity and recalling unused supplies, effectively ending human use in the US [source: McGill OSS 2023]. Science Feedback reports the ban on human testing was lifted in 1966 with restrictions; a Polish fact-check gives research restrictions lasting to 1980 [source: Science Feedback 2025; Demagog 2023] [uncertain: sources differ on the dates of restrictions].
After 1965. An advocacy movement centred on Jacob, the self-styled "father" of DMSO, spread testimonial claims; a 60 Minutes segment in the early 1980s and sports coverage in 1981 drove a surge in self-use among athletes [source: McGill OSS 2023]. Black-market supply was often industrial grade, sometimes made on equipment shared with pesticide production [source: Canadian Force Health Protection sheet; Science Feedback 2025].
2011–2015, USA. An online seller, Lehan Enterprises (Optimum Health Services), sold DMSO creams and roll-ons with claims to treat arthritis, cancer, herpes, glaucoma, cataracts, bladder disease and headaches; after a 2011 joint FDA–FTC warning letter, the Department of Justice filed a complaint in 2015. The complaint cites an email advising a person with prostate cancer against chemotherapy, radiation and surgery and recommending DMSO cream as part of cancer treatment [source: US v. Lehan Enterprises complaint]. The outcome is [uncertain: not verified].
2019, Poland. According to TVN24 as reported by the fact-checker Demagog, a 36-year-old woman died after a treatment at a natural medicine clinic that used DMSO; the report linked above-normal levels of the substance to her death [source: Demagog 2023] [uncertain: secondary report of a news item]. A peer-reviewed forensic report from Poland describes a 37-year-old woman who died after intravenous infusions of DMSO with hydrogen peroxide in a natural-medicine setting: DMSO poisoning was first suspected, but the autopsy and toxicology attributed death to acute cardiopulmonary failure from intravenously given hydrogen peroxide, introduced through an error in preparing the solution [source: Rzepczyk et al. 2023]. Whether the two describe the same death [uncertain].
2020, Australia. The Federal Court restrained MMS Australia and its director, Charles Barton, from advertising and supplying products containing sodium chlorite (MMS), DMSO or yohimbine; the TGA stated these products were not registered and could not lawfully be sold as therapeutic goods [source: TGA 2020].
2020s, social media. Posts presented DMSO as a universal remedy taken by mouth daily for tumours and chronic inflammation, with claims that the FDA blocked it to protect pharmaceutical profits [source: Demagog 2023]. In 2025, an X account, "A Midwestern Doctor", and TikTok videos promoted DMSO for pain, and with ivermectin, fenbendazole or vitamin C for cancer; one post cited a small skin-cancer trial without its caveats [source: Science Feedback 2025].

How it caused harm

Direct reactions. Histamine release and hypersensitivity, including anaphylactoid symptoms [source: Rimso-50 label]. Skin burning, dermatitis and blistering; nausea, vomiting and diarrhoea; headache, sedation, dizziness; transient red-cell breakdown; colour-vision changes; kidney damage is listed by the Canadian sheet [source: Canadian Force Health Protection sheet]. Cardiovascular and respiratory reactions occur mainly with intravenous use; seizures and one severe encephalopathy are reported in medical settings [source: Kollerup Madsen et al. 2019]. A man in his 70s using DMSO for mood and pain had recurrent brain haemorrhage (case report) [source: MSK].
Eye effects. Lens and refractive changes in monkeys, dogs and rabbits on chronic high exposure; the reason for the 1965 action and for eye monitoring in prescribed use [source: Rimso-50 label; McGill OSS 2023]. The systematic review did not find lens changes in human studies [source: Kollerup Madsen et al. 2019].
Carrier effect and contamination. Because DMSO penetrates skin and carries dissolved substances, contaminants in industrial-grade product, including pesticide residues, may be absorbed; some products contain undeclared anti-inflammatories or corticosteroids [source: Canadian Force Health Protection sheet].
Drug interactions. May potentiate other medicines; a laboratory study found it inactivated cisplatin and carboplatin [source: Rimso-50 label; Science Feedback 2025].
Pregnancy. Birth defects in animal studies [source: Rimso-50 label; Canadian Force Health Protection sheet].
Opportunity cost. Disease claims and advice to forgo chemotherapy, radiation or surgery risk delayed effective treatment [source: US v. Lehan Enterprises complaint]. Injured athletes and service personnel may mask injuries and keep training [source: Canadian Force Health Protection sheet].
Psychological and social sequelae [synthesis]: guilt and regret after delayed treatment; family conflict; loss of trust in clinicians; financial loss; embarrassment about odour.
Most at risk: people with cancer, chronic pain or bladder pain; pregnant people; children; people on multiple medicines; people buying industrial or black-market product; athletes and military personnel [source: Canadian Force Health Protection sheet; MSK; synthesis for grouping].

Recognising it today

Phrases and rationales: "miracle cure", "panacea", "the FDA banned it to protect big pharma", "what doctors won't tell you", reliance on testimonials [source: Science Feedback 2025; Demagog 2023; McGill OSS 2023].
Formats: creams, salves, gels and roll-ons sold online; DMSO combined in social-media 'protocols' with ivermectin, fenbendazole, vitamin C or MMS; oral use promoted for many diseases [source: US v. Lehan Enterprises complaint; Science Feedback 2025; TGA 2020; Demagog 2023].
Clinical clues [synthesis]: a garlic-like smell on a client's breath or skin (a known effect: source: Rimso-50 label); skin irritation; mention of 'solvent grade'.
Red flags in a practitioner or group [synthesis]: administering DMSO outside a medical setting (including intravenously); disease claims; advising against oncology care; selling product with sessions; secrecy from doctors; recruitment to resell.
How legitimate uses differ: a prescription bladder instillation for interstitial cystitis under a urologist, with eye and blood monitoring; hospital extravasation management; cryopreservation of cells for transplant; solvent in an approved topical product [source: Rimso-50 label; MSK; Science Feedback 2025].

What to do instead and how to help those harmed

Safer alternatives [synthesis]: route pain, bladder and injury questions to the prescriber, pharmacist or relevant specialist; for cancer, the oncology team and integrative-oncology services that work alongside standard care (entry 172); evidence-based psychological approaches for chronic pain and health anxiety (Domain II).
Assessment of affected clients [synthesis]: ask about current symptoms and urge medical review for any physical effects; screen for depression, anxiety, guilt, regret and trauma after delayed treatment or a bereavement; assess financial harm and ongoing group contact.
Treatment [synthesis]: grief and regret work, self-compassion, family sessions for blame and conflict, rebuilding trust with medical care, support to leave high-pressure groups.
Ethical, reporting and legal duties [synthesis, reporting routes as in 4.11]: report products and disease claims to the medicines regulator and consumer or advertising regulator; report regulated practitioners to their board; follow safeguarding law where children are given products or deprived of care; respect confidentiality and act without consent only where law or imminent risk requires.

Sources

American Psychological Association. Ethical Principles of Psychologists and Code of Conduct (Standard 3.05).

← Previous · XII-142Colloidal silver Next · XII-144 →Apitherapy and bee-venom therapy